Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors

NCT03875313 is registered in ClinicalTrials.gov with Calithera Biosciences, Inc as lead sponsor.

NCT NCT03875313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03875313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
Calithera Biosciences, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
May 20, 2019
Completion date
July 29, 2020
Enrollment
33 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

ccrcc, clear cell renal cell carcinoma, colorectal cancer, crc, rcc, solid tumor, tnbc - triple-negative breast cancer